Neurogene (NGNE)

• Market cap: $143M
• 1 day: -17.59%
• 5 days: -31.66%
• 1 month: -40.47%
• 3 months: -57.84%
• 6 months: -75.84%
• Year to date: -57.84%
• 1 year: -79.37%
• 5 years: -82.13%
• 10 years: -76.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

1% more funds holding

Funds holding: 86 [Q3] → 87 (+1) [Q4]

8% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 25

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

29.95% less ownership

Funds ownership: 106.64% [Q3] → 76.69% (-29.95%) [Q4]

37% less capital invested

Capital invested by funds: $581M [Q3] → $368M (-$214M) [Q4]

44% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $5.52M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $50 418% upside
• Avg. target: $50 418% upside
• High target: $50 418% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 59 / 181 met price target

418% upside $50

Buy Maintained

25 Mar 2025